Opioid Withdrawal Syndrome-Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Opioid withdrawal syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Opioid withdrawal syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Opioid withdrawal syndrome: Overview
Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. Opioids are a group of drugs used for the management of severe pain. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Common signs of opioid withdrawal include: anxiety, goosebumps, restlessness, insomnia, yawning, runny nose, watery eyes, fever, nausea, vomiting, diarrhea and others. The principal site in the brain that triggers the onset of opioid withdrawal syndrome is the locus coeruleus at the base of the brain. At present, the approaches to treat the condition present in opioid withdrawal syndrome treatment market are gradual cessation of an opioid agonist (methadone); Short-term use of a partial mu-opioid agonist (buprenorphine) and detoxification using opioid antagonists (naltrexone and naloxone).
“Opioid withdrawal syndrome - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid withdrawal syndrome pipeline landscape is provided which includes the disease overview and Opioid withdrawal syndrome treatment guidelines. The assessment part of the report embraces, in depth Opioid withdrawal syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid withdrawal syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Opioid withdrawal syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Opioid withdrawal syndrome.
Opioid withdrawal syndrome Emerging Drugs Chapters
This segment of the Opioid withdrawal syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid withdrawal syndrome Emerging Drugs
CHF-6563: Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici is developing a sublingual formulation of CHF-6563. A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study is being developed by Chiesi Farmaceutici S.p.A. to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome.
BXCL501: BioXcel Therapeutics
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia. BXCL501 is being evaluated in the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.
Further product details are provided in the report……..
Opioid withdrawal syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Opioid withdrawal syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Opioid withdrawal syndrome
There are approx. 4+ key companies which are developing the therapies for Opioid withdrawal syndrome. The companies which have their Opioid withdrawal syndrome drug candidates in the most advanced stage, i.e. phase II include,Chiesi Farmaceutici S.p.A..
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Opioid withdrawal syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Opioid withdrawal syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid withdrawal syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid withdrawal syndrome drugs.
Opioid withdrawal syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Opioid withdrawal syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Opioid withdrawal syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Opioid withdrawal syndrome: Overview
Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. Opioids are a group of drugs used for the management of severe pain. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Common signs of opioid withdrawal include: anxiety, goosebumps, restlessness, insomnia, yawning, runny nose, watery eyes, fever, nausea, vomiting, diarrhea and others. The principal site in the brain that triggers the onset of opioid withdrawal syndrome is the locus coeruleus at the base of the brain. At present, the approaches to treat the condition present in opioid withdrawal syndrome treatment market are gradual cessation of an opioid agonist (methadone); Short-term use of a partial mu-opioid agonist (buprenorphine) and detoxification using opioid antagonists (naltrexone and naloxone).
“Opioid withdrawal syndrome - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid withdrawal syndrome pipeline landscape is provided which includes the disease overview and Opioid withdrawal syndrome treatment guidelines. The assessment part of the report embraces, in depth Opioid withdrawal syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid withdrawal syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Opioid withdrawal syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Opioid withdrawal syndrome.
Opioid withdrawal syndrome Emerging Drugs Chapters
This segment of the Opioid withdrawal syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid withdrawal syndrome Emerging Drugs
CHF-6563: Chiesi Farmaceutici S.p.A.
Chiesi Farmaceutici is developing a sublingual formulation of CHF-6563. A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study is being developed by Chiesi Farmaceutici S.p.A. to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome.
BXCL501: BioXcel Therapeutics
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia. BXCL501 is being evaluated in the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.
Further product details are provided in the report……..
Opioid withdrawal syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Opioid withdrawal syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Opioid withdrawal syndrome
There are approx. 4+ key companies which are developing the therapies for Opioid withdrawal syndrome. The companies which have their Opioid withdrawal syndrome drug candidates in the most advanced stage, i.e. phase II include,Chiesi Farmaceutici S.p.A..
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Opioid withdrawal syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Sublingual
- Topical
- Product type
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Opioid withdrawal syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid withdrawal syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid withdrawal syndrome drugs.
Opioid withdrawal syndrome Report Insights
- Opioid withdrawal syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Opioid withdrawal syndrome drugs?
- How many Opioid withdrawal syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid withdrawal syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid withdrawal syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Opioid withdrawal syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chiesi Farmaceutici S.p.A.
- BioXcel Therapeutics
- Aphios Pharmaceutical
- CHF6563
- BXCL501
- APH1501
Introduction
Executive Summary
Opioid withdrawal syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Opioid withdrawal syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Opioid withdrawal syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Opioid withdrawal syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CHF-6563: Chiesi Farmaceutici S.p.A.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
BXCL501: BioXcel Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Opioid withdrawal syndrome Key Companies
Opioid withdrawal syndrome Key Products
Opioid withdrawal syndrome- Unmet Needs
Opioid withdrawal syndrome- Market Drivers and Barriers
Opioid withdrawal syndrome- Future Perspectives and Conclusion
Opioid withdrawal syndrome Analyst Views
Opioid withdrawal syndrome Key Companies
Appendix
Executive Summary
Opioid withdrawal syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Opioid withdrawal syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Opioid withdrawal syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Opioid withdrawal syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CHF-6563: Chiesi Farmaceutici S.p.A.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
BXCL501: BioXcel Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Opioid withdrawal syndrome Key Companies
Opioid withdrawal syndrome Key Products
Opioid withdrawal syndrome- Unmet Needs
Opioid withdrawal syndrome- Market Drivers and Barriers
Opioid withdrawal syndrome- Future Perspectives and Conclusion
Opioid withdrawal syndrome Analyst Views
Opioid withdrawal syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Opioid withdrawal syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Opioid withdrawal syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Opioid withdrawal syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Opioid withdrawal syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
